Reversal of dabigatran by idarucizumab: when and how?

Expert Review of Hematology

Volumn 9, Issue 6, 2016, Pages 519-528

  Vanassche, Thomas ^a   Greinacher, Andreas ^b   Verhamme, Peter ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY MEDICINE GREIFSWALD   (Germany)

Author keywords

anticoagulants; dabigatran; Idarucizumab; NOACs; reversal agent

Indexed keywords

ANDEXANET ALFA; CIRAPARANTAG; DABIGATRAN; FC RECEPTOR; IDARUCIZUMAB; IMMUNOGLOBULIN FC FRAGMENT; ANTICOAGULANT AGENT; ANTITHROMBIN; MONOCLONAL ANTIBODY;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; ATRIAL FIBRILLATION; BINDING KINETICS; BLEEDING; BLOOD CLOT LYSIS; BLOOD CLOTTING DISORDER; CARDIOVASCULAR RISK; DRUG HALF LIFE; DRUG INDICATION; DRUG REVERSAL; EMERGENCY CARE; HUMAN; IN VITRO STUDY; INVASIVE PROCEDURE; KIDNEY FUNCTION; PHARMACODYNAMICS; PRIORITY JOURNAL; THROMBOSIS; URINARY EXCRETION; VENOUS THROMBOEMBOLISM; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD CLOTTING; COMPLICATION; DISEASE MANAGEMENT; DRUG DEVELOPMENT; DRUG EFFECTS; HEMORRHAGE; PRECLINICAL STUDY;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTICOAGULANTS; ANTITHROMBINS; ATRIAL FIBRILLATION; BLOOD COAGULATION; DABIGATRAN; DISEASE MANAGEMENT; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HEMORRHAGE; HUMANS; VENOUS THROMBOEMBOLISM;

EID: 84975270343     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1080/17474086.2016.1184569     Document Type: Article

References (36)

1. N.van Es, M.Coppens, S.Schulman, et al. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood. 2014;124(12):1968–1975.
2. C.T.Ruff, R.P.Giugliano, E.Braunwald, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–962.
3. D.J.Graham, M.E.Reichman, M.Wernecke, et al. Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015;131(2):157–164.
4. J.S.Healey, J.Eikelboom, J.Douketis, et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the randomized evaluation of long-term anticoagulation therapy (RE-LY) randomized trial. Circulation. 2012;126(3):343–348.• Provides data on the frequency of invasive procedures in AF patients under therapeutic dose anticoagulation.
5. J.Beyer-Westendorf, V.Gelbricht, K.Forster, et al. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective dresden NOAC registry. Eur Heart J. 2014;35(28):1888–1896.
6. J.I.Weitz, C.V.PollackJr. Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants. Thromb Haemost. 2015;114(6):1113–1126.
7. D.M.Siegal Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents. J Thromb Thrombolysis. 2015;39(3):395–402.
8. H.Heidbuchel, P.Verhamme, M.Alings, et al. Updated European heart rhythm association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17(10):1467–1507.
9. Praxbind Summary of Product Characteristics [Internet]. Boehringer ingelheim. 2015 [cited 2016 May]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003986/WC500197462.pdf
10. S.J.Connolly, M.D.Ezekowitz, S.Yusuf, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151.
11. J.Stangier, A.Clemens. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost. 2009;15(Suppl 1):9S–16S.
12. J.van Ryn, A.Goss, N.Hauel, et al. The discovery of dabigatran etexilate. Front Pharmacol. 2013;4:12.
13. Dabigatran Summary of Product Characteristics [Internet]. Boehringer ingelheim. [cited 2016 May]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf
14. H.C.Diener, J.D.Easton, C.B.Granger, et al. Design of randomized, double-blind, evaluation in secondary stroke prevention comparing the efficacy and safety of the oral thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with embolic stroke of undetermined source (RE-SPECT ESUS). Int J Stroke. 2015;10(8):1309–1312.
15. S.Schulman, C.Kearon, A.K.Kakkar, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342–2352.
16. S.Schulman, A.K.Kakkar, S.M.Schellong, et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood. 2011;118(21):95–96.
17. A.Majeed, H.G.Hwang, S.J.Connolly, et al. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation. 2013;128(21):2325–2332.
18. S.Werth, T.Breslin, F.NiAinle, et al. Bleeding risk, management and outcome in patients receiving non-VKA oral anticoagulants (NOACs). Am J Cardiovasc Drugs. 2015;15(4):235–242.
19. D.R.Spahn, B.Bouillon, V.Cerny, et al. Management of bleeding and coagulopathy following major trauma: an updated European guideline. Crit Care. 2013;17(2):R76.
20. F.Schiele, J.van Ryn, K.Canada, et al. A specific antidote for dabigatran: functional and structural characterization. Blood. 2013;121(18):3554–3562.•• Detailed description of the structure and function of idarucizumab.
21. J.W.Eikelboom, D.J.Quinlan, J.Van Ryn, et al. Idarucizumab: the antidote for reversal of dabigatran. Circulation. 2015;132(25):2412–2422.
22. S.Glund, V.Moschetti, S.Norris, et al. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost. 2015;113(5):943–951.• Provides the first human in vivo data on idarucizumab.
23. B.R.Curtis, J.Swyers, A.Divgi, et al. Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. Blood. 2002;99(6):2054–2059.
24. A.Greinacher, T.Thiele, K.Selleng. Reversal of anticoagulants: an overview of current developments. Thromb Haemost. 2015;113(5):931–942.
25. S.Glund, J.Stangier, J.Van Ryn, et al. Restarting dabigatran etexilate 24 h after reversal with idarucizumab and redosing idarucizumab in healthy volunteers. J Am Coll Cardiol. 2016;67(13):1654–1656.
26. S.Glund, J.Stangier, M.Schmohl, et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet. 2015;386(9994):680–690.•• Summary of the volunteer studies of idarucizumab including the pharmacokinetic and pharmacodynamic data.
27. C.V.PollackJr., P.A.Reilly, J.Eikelboom, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373(6):511–520.•• First of results of the prospective clinical study on the use of idarucizumab in patients with major bleeding or patients requiring urgent intervention during treatment with dabigatran.
28. M.Jacquemin, J.Toelen, J.Schoeters, et al. The addition of idarucizumab to plasma samples containing dabigatran allows the use of routine coagulation assays for the diagnosis of hemostasis disorders. J Thromb Haemost. 2015;13(11):2087–2092.
29. O.Grottke, M.Honickel, J.Van Ryn, et al. Idarucizumab, a specific dabigatran reversal agent, reduces blood loss in a porcine model of trauma with dabigatran anticoagulation. J Am Coll Cardiol. 2015;66(13):1518–1519.• Provides the experimental setup and results of a large animal model to study bleeding during treatment with dabigatran and its reversal by idarucizumab.
30. S.Y.Na, E.Mracsko, J.Van Ryn, et al. Idarucizumab improves outcome in murine brain hemorrhage related to dabigatran. Ann Neurol. 2015;78(1):137–141.• Animal study on the effects of idarucizumab on brain hemorrhage under dabigatran treatment.
31. S.Glund, J.Stangier, M.Schmohl, et al. Idarucizumab, a specific antidote for dabigatran: immediate, complete and sustained reversal of dabigatran induced anticoagulation in elderly and renally impaired subjects. Blood. 2014;124(21):344.•• Phase II study of idarucizumab in elderly volunteers and individuals with impaired renal function providing clinically highly relevant data for these subgroups.
32. C.V.PollackJr., P.A.Reilly, R.Bernstein, et al. Design and rationale for RE-VERSE AD: a phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost. 2015;114(1):198–205.• Describes the background and the rational of the study design for the clinical study with idarucizumab in patients.
33. J.E.Ansell, S.H.Bakhru, B.E.Laulicht, et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med. 2014;371(22):2141–2142.
34. B.Laulicht, S.Bakhru, S.Steiner, et al. PER977 (ciraparantag) reverses edoxaban anticoagulation at steady state and has no effect on re-anticoagulation at the next scheduled dose. Eur Heart J. 2015;36:859–860.
35. K.Ghadimi, K.E.Dombrowski, J.H.Levy, et al. Andexanet alfa for the reversal of factor Xa inhibitor related anticoagulation. Expert Rev Hematol. 2016;9(2):115–122.
36. D.M.Siegal, J.T.Curnutte, S.J.Connolly, et al. Andexanet alfa for the reversal of factor xa inhibitor activity. N Engl J Med. 2015;373(25):2413–2424.